VOR·Vor Biopharma Inc.
VOR|Analyst Targets
VOR|Insider Trading
VOR|Fundamentals
VOR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-0.72 | $-0.90 | -25.3% |
| Q3'25 | $-4.10 | $-121.63 | -2866.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | - | $0 | - |
| Q3'25 | - | $0 | - |
VOR|Monthly Returns
Market Data
VOR Stock Snapshot
- Market cap
- 1.00B
- P/E ratio
- 1.6
- Day range
- $18.33 – $19.80
- News sentiment
- 51/100 · Neutral
- Analyst target
- $39.00 (+100.2%)
- Consensus
- Strong Buy · 16 analysts
Price action on VOR is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.
Behaviour On Record
What VOR's own history says about today's numbers
- Realized volatility (21d)
- 59.9% 11th pct
- Below its peak
- -98.2%
- vs 200-day average
- +14.9%
- Up days (1y)
- 44%
Vor Biopharma Inc. is currently running 59.9% annualised volatility over the last 21 sessions. Measured against VOR's own 5 years of daily returns rather than a market-wide average, that is the 11th percentile — unusually subdued by its own history, against a typical reading of 82.2%.
VOR is trading -98.2% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -76.8%, and the deepest was -79.0% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits +14.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 88th percentile — a wider gap than this stock usually carries. Over the past year VOR closed higher on 44% of sessions, and it is currently 1 session into a falling streak.
On November specifically: over 5 years of records, VOR finished the month higher 2 of 5 times, with a median return of -1.9% and an average of -7.6%. Its strongest month historically has been December at +30.1% on average, its weakest April at -14.0%.
Overnight risk is measurable too: VOR has opened more than 2% away from the prior close in 441 of 1,330 sessions (33.2% of the time), with the largest gaps running +30.7% and -58.8%.
All figures computed from 1,333 daily closes between 2021-02-08 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against VOR's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of VOR's sector?
Vor Biopharma Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, VOR ranks 7th of 15 tracked industries, weakening.
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 100
- Industry rank
- #7 of 15
Analyst Consensus Estimates
What do analysts expect VOR to earn?
Analysts expect Vor Biopharma Inc. to earn -$7.86 per share in the fiscal year ending Dec 2026 and -$2.05 in the fiscal year ending Dec 2029, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on VOR?
William Blair most recently initiated coverage on Vor Biopharma Inc. to Outperform on Oct 21, 2026. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- William Blair: Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in VOR?
Johnson & Johnson reports a stake in Vor Biopharma Inc. on SEC Form 13F: 53.7K shares, about 0.10% of the company, worth $1.0M at the end of Q3 2026. At today's price that stake is worth $1.0M, about 0.00% of JNJ's own market value.
- Holder
- JNJ
- Shares held
- 53.7K
- Stake
- 0.10%
- Value
- $1.0M
| Holder | Last quarter | Shares | % of VOR | Value at filing | Value now | Change |
|---|---|---|---|---|---|---|
| Johnson & Johnson JNJ | 53.7K | 0.10% | $1.0M | $1.0M | +2.1% |
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did Vor Biopharma Inc.'s latest earnings release say?
Most important lines
- 1
-7.5 -6.3 -7.5 -1.6 -6.4 Mean change from baseline (95% CI) MEAN CHANGE IN MG-ADL SCORE OLE Period Patients in placebo group switched to telitacicept* Telitacicept Demonstrated Durable MG-ADL Over Time Sustained and deepening functional improvement through 48 weeks RemeGen-sponsored trial -7.5 * Telitacicept arm continue with the same treatment, Placebo arm switched to Telitacicept during OLE period.
- 2
Telitacicept Demonstrated the Strongest ESSDAI Improvement in SD Largest placebo-adjusted ESSDAI reduction observed across Phase II and III datasets -4.3 PBO-adjusted LSM ESSDAI Change from Baseline Efgartigimod - RHO; Nipocalimab - Bowman 2022, Lancet; Ianalumab - St. Clair 2024, Nature and Grader-Beck 2025 ACR; Dazodalibep - Xu 2024 Rheumatology; Ianalumab Phase 3 – ACR 2025 SD, Sjogren's disease; ESSDAI, EULAR Sjögren’s syndrome disease activity index n=14 n=23 n=47 n=36 n=14 Based on historical clinical data; not a head-to-head trial RemeGen-sponsored trial n=305 n=127 Phase III Datasets Phase II Datasets ? -3.8
- 3
Commercial Approvals †Conditional Approval, Full Approval in 2023; *Accelerated Approval in China Established Efficacy in China Across Autoimmune Diseases BLA Submissions Best-In-Disease 3 2 3 2021 - Systemic Lupus Erythematosus (SLE)† 2024 - Rheumatoid Arthritis (RA) 2025 - Myasthenia Gravis (MG) Filed 2025 – Sjögren’s Disease (SD) Filed 2025 – IgA Nephropathy (IgAN)* Validated Commercial Therapy in China Across Diverse Autoimmune Diseases Poised to Further Expand Telitacicept Footprint in Large, Underserved Diseases in China Unique Dual BAFF/APRIL Inhibition Drives Superior Clinical Benefit Systemic Lupus Erythematosus Myasthenia Gravis Sjögren’s Disease
News & sentiment
What is the news saying about VOR?
VOR rose 6.5% over the month to Nov 6. News tone held between 0 and 79 from Oct 8 to Oct 22, then dropped to 59 on Oct 30.
- Oct 16 -7.3%
- Oct 27 +9.2%
- Nov 5 -7.3%
Technical analysis
How strong is VOR's momentum right now?
On the daily chart VOR ranks at the 17th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling VOR?
30 of the 34 tracked managers added to VOR in their latest 13F and 4 trimmed. Together they own 13.5% of the company, worth $128.3M. State Street and Vanguard Capital Management alone hold 9.1%.
- 1State Street Corp5.07%$48.2M positionAdded 133.9% last quarter
- $38.4M positionAdded 45.4% last quarter
- 3UBS Group AG0.96%$9.1M positionAdded 1.0% last quarter
- 4Woodline Partners LP0.74%$7.0M positionAdded 352.4K shares last quarter
- $6.3M positionNew position last quarter
- $5.5M positionAdded 62.1% last quarter
- $2.2M positionAdded 446.4% last quarter
- $1.9M positionTrimmed 0.2% last quarter
- 9Nuveen, LLC0.18%$1.7M positionNew position last quarter
- 10RhumbLine Advisers0.11%$1.1M positionNew position last quarter
Discover more
How has VOR done against its peers?
Over the six months to Nov 6, VOR returned +21.8%. Of the 15 related stocks and ETFs, 11 did better, led by MRNA at +438.3%.
- 1MRNAModerna, Inc.up 438.3%+416.5 pts
- 2ARKGARK Genomic Revolution ETFup 45.8%+24.1 pts
- 3AMGNAmgen Inc.up 39.4%+17.6 pts
- 4ROIVRoivant Sciences Ltd.up 35.5%+13.8 pts
- 5RPRXRoyalty Pharma plcup 34.8%+13.1 pts
- 6BIIBBiogen Inc.up 30.0%+8.3 pts
- 7RVMDRevolution Medicines, Inc.up 28.0%+6.3 pts
- 8VRTXVertex Pharmaceuticals Incorporatedup 27.9%+6.2 pts
- 12VORThis stockup 21.8%
- 16INSMInsmed Incorporateddown 21.2%−43.0 pts
